« Back
Home /
PT-2385

PT-2385

Item no.	HY-12867-5mg
Manufacturer	MedChem Express
CASRN	1672665-49-4
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 2 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Breast Cancer Testicular & Prostate Cancer
Type	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Eli Wallace, Ph.D. PT2385: HIF-2α Antagonist for the Treatment of VHL Mutant ccRCC. 12th International VHL Medical Symposium April 8, 2016.\|[2]Xie C, et al. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23(11):1298-1308.\|[3]Wallace EM, et al. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76(18):5491-500.
Smiles	N#CC1=CC(F)=CC(OC2=CC=C(S(=O)(C)=O)C3=C2CC(F)(F)[C@H]3O)=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1672665-49-4
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	HIF/HIF Prolyl-Hydroxylase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	383.34
Product Description	PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 50 mg/mL
Manufacturer - Pathway	Metabolic Enzyme/Protease
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12867-5mg-safety-datasheet.pdf